Biblio Discovery — Demo Discovery Service

46 hasil untuk "Andreas Pinter"

Menampilkan 1–20 · 2,38 detik · RSS

  1. Artikel Jurnal

    Best Responders and Super-Responders to Calcipotriol and Betamethasone Dipropionate PAD-Cream: A Post Hoc Pooled Analysis of Two Phase 3 Trials

    Andreas Pinter; Jordi Galván; Frank Freischläger

    Dermatology and Therapy, Vol. 15 No. 6 · 2025 · Inggris · DOAJ Scopus

    Abstract Introduction Individual endpoints from phase 3 trials demonstrated high efficacy and convenience for the calcipotriol/betamethasone dipropionate (CAL/BDP) cream based on polyaphron dispersion (PAD) technology compared to CAL/BDP gel. The objectives are to assess the proportion of best…

  2. Artikel Jurnal

    A New Restrictive Composite Endpoint to Assess Best Response in Patients with Mild-to-Moderate Psoriasis Treated with CAL/BDP PAD-Cream: A Case Series

    Andreas Pinter; Jordi Galván; Frank Freischläger

    Case Reports in Dermatology, Pp 1-14 (2026) · 2026 · Inggris · DOAJ Scopus

    Introduction: In the assessment of a psoriasis treatment, traditional endpoints evaluated independently may not fully capture the multidimensional nature of treatment response. Best response to calcipotriol/betamethasone dipropionate (CAL/BDP) cream based on polyaphron dispersion (PAD) technology…

  3. Artikel Jurnal

    Management of Paediatric Psoriasis by Paediatricians: A Questionnaire-Based Survey

    Andreas Pinter; Nicole Mielke; Bartosz Malisiewicz dkk.

    Dermatology and Therapy, Vol. 10 No. 4 · 2020 · Inggris · DOAJ Scopus

    Abstract Introduction Paediatric plaque psoriasis (PedPso) in children and adolescents is often diagnosed and treated for the first time by paediatricians. An early onset of psoriasis is associated with a genetic family burden, higher severity of disease and increased risk of comorbidities…

  4. Artikel Jurnal

    Efficacy and Safety of Topical Tacrolimus Microemulsion Applied Twice Daily in Patients with Mild to Moderate Scalp Psoriasis

    Andreas Pinter; Athanasios Tsianakas; Adina Eichner dkk.

    Dermatology and Therapy, Vol. 14 No. 2 · 2024 · Inggris · DOAJ Scopus

    Abstract Introduction Involvement of the scalp is common in psoriasis and severely affects the quality of life of those affected. It is difficult to treat and places special demands on the galenics of a drug formulation. Tacrolimus is a calcineurin inhibitor and is approved as an ointment…

  5. Artikel Jurnal

    Tolerability and Efficacy of a Medical Device Repairing Emollient Cream in Children and Adults with Mild to Moderate Atopic Dermatitis

    Andreas Pinter; Marie-Dominique Thouvenin; Adeline Bacquey dkk.

    Dermatology and Therapy, Vol. 9 No. 2 · 2019 · Inggris · DOAJ Scopus

    Abstract Introduction Regular emollient application is recommended for managing atopic dermatitis (AD). Although many emollients are available, only AD-tested medical device repairing emollient creams (MDRECs) can be recommended for treating and preventing AD skin lesions. Here, we evaluated the…

  6. Artikel Jurnal

    ERAPSO: Revealing the High Burden of Obesity in German Psoriasis Patients

    Peter E. H. Schwarz; Andreas Pinter; Nima Melzer dkk.

    Dermatology and Therapy, Vol. 9 No. 3 · 2019 · Inggris · DOAJ Scopus

    Abstract Introduction Plaque psoriasis is a chronic, systemic-inflammatory disease characterized by skin erythema, plaques and scaling, and is associated with different comorbidities like psoriatic arthritis, obesity, and cardiometabolic diseases. Obesity aggravates cardiovascular risk in psoriasis…

  7. Artikel Jurnal

    Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator’s Global Assessment: A Post Hoc Analysis of a Phase 3 Trial

    Michael J. Cork; Benjamin Lockshin; Andreas Pinter dkk.

    Acta Dermato-Venereologica, Vol. 104 · 2024 · Inggris · DOAJ Scopus

    In young children, atopic dermatitis (AD) imposes a multidimensional burden on many aspects of their quality of life (QoL) and that of their families. LIBERTY AD PRESCHOOL part B was a randomized, double- blinded, placebo-controlled phase 3 trial in 162 children (aged 6 months to 5 years) with…

  8. Artikel Jurnal

    Adherence to CAL/BDP PAD-Cream Influences Treatment Effectiveness and Preference in Scalp Psoriasis Under Real-Life Conditions: Results from the Prospective, Multicenter, Observational PRO-SCALP Study

    Anthony Bewley; Andreas Pinter; José Luis López Estebaranz dkk.

    Dermatology and Therapy, Vol. 16 No. 9 · 2026 · Inggris · DOAJ Scopus

    Abstract Introduction Scalp psoriasis is often associated with poor adherence to topical therapy. A novel formulation of calcipotriol and betamethasone dipropionate based on polyaphron dispersion (CAL/BDP PAD-cream) showed improved outcomes and satisfaction in the PRO-SCALP study, particularly in…

  9. Artikel Jurnal

    Patient and Clinician‐Reported Outcomes and Adherence to Calcipotriene/Betamethasone Dipropionate PAD‐Cream in Treatment of Scalp Psoriasis in Adults: An Interim Analysis of the PRO‐SCALP Study

    Andreas Pinter; Jose Luis López Estebaranz; Anthony Bewley dkk.

    JEADV Clinical Practice, Vol. 4 No. 4 · 2025 · Inggris · DOAJ Scopus

    ABSTRACT Background Effective management of scalp psoriasis needs treatment with high patient preference and treatment satisfaction. Clinical trials show promising results for calcipotriene and betamethasone dipropionate cream based on polyaphron dispersion (PAD) technology (CAL/BDP PAD‐cream)…

  10. Artikel Jurnal Teks lengkap

    Influenza Vaccination in Psoriatic Patients—Epidemiology and Patient Perceptions: A German Multicenter Study (Vac-Pso)

    Christian Kromer; Phoebe Wellmann; Ralf Siemer dkk.

    Vaccines, Vol. 9 No. 8 · 2021 · Inggris · DOAJ Scopus

    The risk of developing severe complications from an influenza virus infection is increased in patients with chronic inflammatory diseases such as psoriasis (PsO) and atopic dermatitis (AD). However, low influenza vaccination rates have been reported. The aim of this study was to determine…

  11. Artikel Jurnal

    Real-World Long-Term Effectiveness of Risankizumab Among Patients with Moderate-to-Severe Psoriasis: Analysis from an International Medical Chart Review (RAPID) Study

    Andreas Pinter; Ahmed M. Soliman; Irina Pivneva dkk.

    Dermatology and Therapy, Vol. 14 No. 5 · 2024 · Inggris · DOAJ Scopus

    Abstract Introduction Real-world data on the efficacy of risankizumab (RZB) in clinical moderate-to-severe plaque psoriasis (PsO) are limited. The RAPID study assessed real-world clinical and patient-reported outcomes in RZB-treated PsO patients using data collected from dermatologists in Canada…

  12. Artikel Jurnal

    Hidradenitis Suppurativa and Concurrent Psoriasis: Comparison of Epidemiology, Comorbidity Profiles, and Risk Factors

    Andreas Pinter; Georgios Kokolakis; Juergen Rech dkk.

    Dermatology and Therapy, Vol. 10 No. 4 · 2020 · Inggris · DOAJ Scopus

    Abstract Introduction Hidradenitis suppurativa (HS) is a chronic, debilitating, and inflammatory skin disease. The epidemiology of HS varies greatly, with an estimated prevalence ranging from 0.03% to 4% worldwide. Similar to psoriasis (PsO), HS also exhibits a systemic inflammatory nature with a…

  13. Artikel Jurnal

    Treatment Discontinuation in Patients with Psoriasis Treated with Biologics: A Retrospective Analysis of German Health Claims Data

    Andreas Pinter; Ahmed M. Soliman; Karina C. Manz dkk.

    Dermatology and Therapy, Vol. 14 No. 6 · 2024 · Inggris · DOAJ Scopus

    Abstract Introduction Plaque psoriasis is a common, often debilitating, chronic autoimmune inflammatory skin disease. Moderate-to-severe forms of psoriasis can be treated with biologics such as anti-interleukin and anti-tumor necrosis factor antibodies. We aimed to investigate treatment…

  14. Artikel Jurnal

    Real-World Discontinuation and Switching Patterns for Interleukin-Inhibitor Treatments in Patients with Moderate-to-Severe Psoriasis in Japan

    Yayoi Tada; Ahmed M. Soliman; Kanako Ishii dkk.

    Dermatology and Therapy, Vol. 14 No. 1 · 2023 · Inggris · DOAJ Scopus

    Abstract Introduction Patients with moderate-to-severe psoriasis (PsO) treated with interleukin (IL)-inhibitors may require treatment modification to achieve disease control. This study evaluated discontinuation and switching of IL-inhibitors for PsO patients in Japan. Methods Japan Medical Data…

  15. Artikel Jurnal

    Calcipotriene and Betamethasone Dipropionate PAD-Cream Demonstrates Greater Treatment Efficacy in Patients with Moderate-to-Severe Psoriasis Compared to Topical Suspension/Gel: A Subgroup Analysis of Two Phase 3 Studies

    Linda Stein Gold; Andreas Pinter; April Armstrong dkk.

    Dermatology and Therapy, Vol. 13 No. 9 · 2023 · Inggris · DOAJ Scopus

    Abstract Introduction Psoriasis ranges from mild to severe with the majority of patients having mild disease. Mild to moderate disease is often treated with topical therapies while photo-, oral, and biologic therapies are generally reserved for moderate-to-severe disease. There is a strong…

  16. Artikel Jurnal

    A Delphi Consensus on Tildrakizumab Dosing and Titration in Moderate-to-Severe Plaque Psoriasis

    Julia-Tatjana Maul; Maria Concetta Fargnoli; Spyridon Gkalpakiotis dkk.

    Acta Dermato-Venereologica, Vol. 106 · 2026 · Inggris · DOAJ Scopus

    Tildrakizumab is approved for moderate-to-severe plaque psoriasis in 2 doses, 100 mg and 200 mg, with comparable safety profiles. This study aimed to establish pan-European consensus on optimal tildrakizumab dosing and titration using a modified Delphi methodology. A steering group of 8 European…

  17. Artikel Jurnal

    Treatment switching and associated economic outcomes in patients with plaque psoriasis treated with biologics: A retrospective analysis of German claims data 2016−2021

    Andreas Pinter; Ahmed M. Soliman; Karina C. Manz dkk.

    JEADV Clinical Practice, Vol. 3 No. 5 · 2024 · Inggris · DOAJ Scopus

    Abstract Background Biologics are therapeutic options for the management of moderate−severe plaque psoriasis. Some patients need to switch biologic treatment to achieve satisfactory outcomes, which might have a considerable economic impact. Objectives We assessed the characteristics and switch…

  18. Artikel Jurnal Teks lengkap

    Low Pneumococcal Vaccination among Patients with Psoriasis in Germany: Results from Vac-Pso

    Phoebe Wellmann; Christian Kromer; Ralf Siemer dkk.

    Vaccines, Vol. 10 No. 7 · 2022 · Inggris · DOAJ Scopus

    While suboptimal pneumococcal vaccination rates have been reported in immunosuppressed patients with rheumatic diseases, data for patients with psoriasis (PsO) or atopic dermatitis (AD) are scarce. Pneumococcal vaccination in Germany is recommended in patients with certain comorbidities…

  19. Artikel Jurnal

    Real-World Evidence for the Impact of Minimal Disease Activity on Quality of Life in Atopic Dermatitis: An Interim Analysis of the Prospective, Multicenter, Non-Interventional UP-TAINED Study

    Felix Lauffer; Boris Bauer; Katharina Kreutzer dkk.

    Dermatology and Therapy, Vol. 16 No. 9 · 2026 · Inggris · DOAJ Scopus

    Abstract Introduction Minimal disease activity (MDA) has recently been introduced as comprehensive treatment target in atopic dermatitis (AD), integrating both clinician- and patient-reported outcomes. Evidence on the real-world feasibility and impact of achieving MDA on quality of life (QoL)…